Risperdal Gynecomastia Settlement Reached As Trial Gets Underway In Philadelphia

Only a few hours after trial began this week in Philadelphia for a product liability lawsuit brought by a young man who claims he experienced male breast growth from Risperdal side effects, Johnson & Johnson has reportedly agreed to settle the case. 

The trial involved a claim brought by Christopher Walker, who indicates that he developed a medical condition known as gynecomastia following use of the atypical antipsychotic, alleging that Johnson & Johnson failed to adequately warn consumers and the medical community.

Gynecomastia involves the full development of breasts among teen boys and young adult males, often resulting in the need for surgical removal and causing severe psychological injury.

Learn More About

Risperdal Lawsuits

Side effects of Risperdal linked to risk of breast growth among young boys, or gynecomastia.

Learn More About this Lawsuit SEE IF YOU QUALIFY FOR COMPENSATION

The case is one of roughly 1,300 similar Risperdal gynecomastia lawsuits pending in Pennsylvania state court, and was the third in a series of bellwether trials scheduled to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation.

In February 2015, the first Risperdal bellwether trial in Pennsylvania ended in a $2.5 million jury award, with a second case the following month ending with a defense verdict. While that second jury found that the plaintiff failed to establish that his abnormal breast growth was caused by the medication, the same jury determined that Johnson & Johnson failed to adequately warn the boys and their parents about the gynecomastia risks.

While the outcomes of the cases are not binding on other claims, they are being closely watched by lawyers involved in the litigation, as they may influence negotiations to reach Risperdal gynecomastia settlements that would avoid the need for hundreds of individual trials to be scheduled.

Johnson & Johnson has been quietly dealing with breast growth litigation over Risperdal for years, but the number of cases has continued to grow as more families and young adults learn that there may be a link between problems suffered following a diagnosis of gynecomastia and Risperdal use as a child.

In 2012, a different series of cases were scheduled to go before juries in Philadelphia, but the drug maker reached agreements to settle the Risperdal lawsuits just as the trials were set to begin.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted yesterday)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted 2 days ago)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.